ARTICLE | Company News
Otsuka Pharmaceutical, Medimetriks deal
February 15, 2016 8:00 AM UTC
Otsuka granted Medimetriks exclusive rights to develop and commercialize OPA-15406 in the U.S. The phosphodiesterase-4 (PDE-4) inhibitor has completed a Phase II trial for atopic dermatitis. Otsuka ...